Introduction
============

Renal cell carcinoma (RCC) is one of the most common malignant tumors. The incidence of RCC is rising gradually, both in the United States and China. It is estimated that there will be 61 560 new cases of kidney and renal pelvis cancer in the United Sates in 2015 [@B1]. Over the last 10 years, many basic and clinical studies have demonstrated that RCC is one of a subset of cancers related to obesity and adipose tissue [@B2]. High body mass index (BMI) is associated with a higher risk of developing RCC [@B3]; however, patients with a higher BMI have a relatively longer overall survival, cancer-specific survival and recurrence-free survival [@B4]. The authors of these articles pointed out that obesity-related factors may be promising in understanding RCC and may have some translational application potential. In our previous study, we found that in the Chinese population, visceral fat accumulation (VFA) was mainly observed in clear cell renal cell carcinoma (ccRCC) patients but not in non-ccRCC patients [@B5]. However, the mechanism behind this phenomenon remains unknown.

Adiponectin is a 30-kD protein secreted by white adipose tissue (WAT). The adiponectin concentration in plasma can reach up to 2-10 µg/ml in humans [@B6]. This means it can be easily detected, and it has a potential use in diagnosis or prognostication in some diseases, including RCC. Apart from adiponectin, adipose tissue also produces a variety of inflammation-related factors, including leptin, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6).

Several studies focusing on the relationship between RCC and adiponectin or other obesity-related factors have come to some preliminary conclusions. Pinthus et al. found that lower plasma adiponectin levels are associated with larger tumor size and metastasis in ccRCC[@B7]. Chou et al. suggested the adiponectin receptor 1 (AdipoR1) was more ubiquitously expressed in RCC tissues [@B8]. Some scientists verified the inverse association of leptin levels with RCC [@B9], and others confirmed that the relationship between serum leptin level and RCC may differ by ethnicity [@B10]. These studies indicate that adiponectin or leptin may play an important role in the interlinkage between obesity and RCC.

In this study, we examined whether adiponectin, leptin and VFA have some correlation with subtypes, grades, or pathological status of RCC, and we explored the "obesity-WAT-adiponectin/leptin-RCC" chain in defining different subtypes of RCC for further research use and translational applications.

Methods
=======

Patients
--------

We recruited consecutive patients who underwent radical or partial nephrectomy in our department from September 2011 to June 2013. The patients were all adults (\> 18 years) diagnosed with malignant renal tumors. We excluded patients whose abdominal computed tomography images were not available and those whose pathological results had not been confirmed. Because of cachexia, we also excluded patients with metastatic renal tumors. Then we excluded patients with clinical characteristics that we were concerned about but which were incomplete. After testing the serum adiponectin level and leptin level, we excluded patients whose adiponectin concentration or leptin concentration was in the highest 5% or lowest 5% among all the patients, because these extreme data are usually due to measurement errors. Finally, 198 patients met our criteria and they all signed written informed consent forms to participate in the study. Additionally, we also enrolled 86 people who had no cancer or cancer-related diseases as normal controls. We collected their blood and tested their serum adiponectin and leptin levels.

Histological subtypes of malignant RCC included clear-cell, papillary, chromophobe and unclassified RCC, according to the 2004 World Health Organization classification of renal tumors [@B11]. Each slide was retrieved and examined by two experienced genitourinary pathologists blinded to the patient\'s clinical details.

We measured body weight (kg) and height (m) at the same time, and the BMI was calculated as the weight in kilograms divided by the height in square meters. The definitions and calculation of total fat area (TFA), subcutaneous fat area (SFA) and visceral fat area (VFA) were the same as described in our previously published article [@B5].

Measurement of plasma adiponectin and leptin
--------------------------------------------

We collected patients\' blood samples in the morning and after separation stored these samples at -80°C until they were analyzed. We use an enzyme-linked immunosorbent assay (ELISA) kit (ab108786, Abcam, Cambridge, USA), which is specific for human adiponectin, to detect the level of adiponectin in patients\' plasma according to the manufacturers\' instructions. Each sample was detected in triplicate. Inter-assay precision was tested and found to be greater than 95%. The detection of plasma leptin concentration was the same as that described above, using a human-specific leptin ELISA kit (EK1972, Multisciences, Shanghai, China).

Statistical analysis
--------------------

Sex, smoking status, grades of ccRCC (Fuhrman I and II vs Fuhrman III and IV), hypertension, diabetes, BMI \< 27 vs ≥ 27 kg/m^2^ for men and \< 25 and ≥ 25 kg/m^2^ for women (the threshold points for obesity in Asia) [@B12] were considered to be binary variables and presented as proportions. In patients with malignant RCC, pathological subtypes were checked to determine the presence of ccRCC or other types. Age, tumor size, the concentration of serum adiponectin and leptin, VFA, SFA, TFA and VFA% (VFA/TFA × 100%) were counted as continuous variables and reported in the form of a median (range).

We used linear regression analysis to explore if the serum levels of adiponectin or leptin were linearly correlated with VFA. Unconditional logistic regression models were developed to find any relationship between age, sex, smoking status, hypertension, diabetes, serum levels of adiponectin and leptin, VFA, BMI or pathology (ccRCC or other). We used both univariate and multivariate analysis. Continuous data were compared with Student\'s t test when the data matched the criteria of normal distribution and are presented as mean ± standard deviation (SD) in the graphs. Because the serum level of adiponectin was not distributed normally, we used a nonparametric test (Mann-Whitney U) for comparison. All tests were two-sided and p values less than 0.05 were considered statistically significant. We used SPSS statistic software, version 19.0 (SPSS Inc., Chicago, IL, USA) to analyze the data.

Results
=======

In total, 284 people participated in our study, including 198 RCC patients and 86 normal controls. The patient demographic and clinical characteristics are summarized and presented in Table [1](#T1){ref-type="table"}. In the RCC patients\' group, the median age was 54 years old and men accounted for 70.7%. One hundred fifty-six patients (78.8%) had ccRCC and 42 patients had other subtypes of RCC, including four with papillary (2.0%), 28 with chromophobe (14.1%) and 10 with unclassified RCC (5.1%). The mean BMI was 24.31 kg/m^2^ and the mean VFA was 100.32 cm^2^. The mean serum adiponectin, leptin level and VFA of different histological types of RCC are shown in Fig. [1](#F1){ref-type="fig"}.

In the normal control group, the median age was 56 years old and men accounted for 69.8%. The mean BMI of cancer-null patients is 24.23 kg/m^2^ in this database. There was no significant difference between the RCC patients\' group and normal controls\' group in sex, age and BMI. However, cancer-null patients had significantly higher circulating adiponectin and leptin levels than RCC patients (p \< 0.001), just as previously reported by other research teams [@B9], [@B13].

We then examined whether there were significant differences between ccRCC patients and non-ccRCC patients in the aspects of VFA or serum levels of leptin and adiponectin. We observed lower adiponectin levels in patients with ccRCC (median, 6.01 µg/ml; SD ± 3.94) compared with patients with non-ccRCC (median, 8.11 µg/ml; SD ± 4.97), a statistically significant difference (p = 0.004) (Fig. [2](#F2){ref-type="fig"}a, Table [2](#T2){ref-type="table"}). Significantly greater VFA (p = 0.042) was also observed in ccRCC patients (median, 107.79 cm^2^; SD ± 44.63) than in non-ccRCC patients (median, 78.85 cm^2^; SD ± 47.27) (Fig. [2](#F2){ref-type="fig"}b, Table [2](#T2){ref-type="table"}). However, there was no significant difference (p = 0.940) in serum leptin levels between ccRCC (median, 4039.31 pg/ml; SD ± 2319.33) and non-ccRCC patients (median, 3883.26 pg/ml; SD ± 2312.54) (Fig [2](#F2){ref-type="fig"}c, Table [2](#T2){ref-type="table"}).

We then performed linear correlation analysis to determine if serum adiponectin or leptin concentration had some linear linkage with VFA. Results from Pearson\'s tests showed that the correlation between VFA and serum adiponectin level (p \< 0.001) and between VFA and serum leptin concentration (p \< 0.001) were both statistically significant (Fig. [3](#F3){ref-type="fig"}a & 3b).

We used univariate and multivariate logistic regression analysis to identify predictors that had the potential to differentiate ccRCC from non-ccRCC patients. The regression results are shown in Table [3](#T3){ref-type="table"}. We used the pathological characteristics (ccRCC or non-ccRCC) as a binary dependent variable. In univariate analysis, female sex (OR = 0.460, 95% CI 0.226-0.934, p = 0.032), greater VFA (OR = 0.992, 95% CI 0.984-1.000, p = 0.044) and lower serum adiponectin level (OR = 1.120, 95% CI 1.037-1.209, p = 0.004) were considered to be significant factors in predicting ccRCC. We used the following factors in our multivariate regression analysis: age, BMI, VFA, adiponectin level, leptin level, sex, smoking status, hypertension and diabetes. The first five factors were viewed as continuous variables while the last four factors were considered binary variables. Our results showed that only serum adiponectin level (OR = 1.120, 95% CI 1.037-1.209, p = 0.004) was an independent predictor for ccRCC.

We observed that men with ccRCC had lower leptin (p \< 0.001) and adiponectin (p = 0.002) levels than women (Table [4](#T4){ref-type="table"}). Obese patients had higher serum leptin levels (p \< 0.001), and diabetic patients had lower plasma adiponectin levels (p = 0.001) (Table [4](#T4){ref-type="table"}). Additionally, patients with greater than 90 cm^2^ VFA had higher circulating leptin levels, a statistically significant difference (p \< 0.001). These patients also had lower plasma adiponectin levels (p = 0.040). However, these two factors had no association with tumor size or Fuhrman grades among ccRCC patients (Table [4](#T4){ref-type="table"}).

Discussion
==========

In this study, we demonstrated that a lower plasma adiponectin level may be a predictor for differentiating ccRCC from non-ccRCC. We showed that compared with other types of RCC, ccRCC patients have a lower plasma adiponectin level and greater VFA (Fig. [2](#F2){ref-type="fig"}a & Fig. [2](#F2){ref-type="fig"}b). We also found a clear inverse linear correlation between VFA and plasma adiponectin concentration. Furthermore, among patients with ccRCC, we observed a significantly higher leptin level in obese people. In the ccRCC subgroup, we also found that people with diabetes had a lower plasma adiponectin level. For ccRCC patients with a VFA ≥ 90 cm^2^, we observed a significantly higher leptin level and a lower adiponectin level. Neither plasma adiponectin nor leptin levels were significantly correlated with tumor size or Fuhrman grade in ccRCC patients.

It has been previously noted that obesity is associated with RCC. In one study it was reported that obesity could increase the risk of RCC in both men and women by up to 1.7-fold and 4.75-fold, respectively [@B14]. In a recent meta-analysis, similar results were reported [@B15]. Other research groups suggested that obesity, defined as a high BMI, was an independent predictor for ccRCC in patients with a renal cortical tumor [@B16], [@B17]. Equally important, some researchers found that BMI could help differentiate ccRCC from non-ccRCC [@B16]. However, BMI represents the overall condition of a patient, while visceral fat is involved in the biological functions. It is believed that visceral obesity is strongly associated with an increased risk of insulin resistance, metabolic syndrome and cardiovascular disease, independently from BMI [@B18]. Therefore, focusing on VFA and its associated adipokines is a better choice for understanding the link between obesity and the origin of RCC. In our previous study, we found that VFA was associated with different pathological subtypes of RCC [@B5] and that there are significant relationships between the percentage of visceral adipose tissue and both tumor size and higher Fuhrman grades [@B19]. The results of the current study are an extension of our previous findings.

So far, no direct mechanism defining how VFA alters the pathophysiology of RCC has been discovered, what we know is that VFA decreases the expression of adiponectin, a well-known metabolically active polypeptide [@B20]. Researches have revealed that adiponectin has insulin-sensitizing, anti-inflammatory, antiatherosclerotic and anticancer properties [@B21]. An inverse correlation between circulating adiponectin level and the incidence of RCC has been observed [@B13] and a low concentration of adiponectin is significantly associated with a larger tumor size and a risk of metastasis, particularly in ccRCC [@B7].

However, it has been unclear if the circulating adiponectin level could be used to discriminate ccRCC from non-ccRCC. In this study, we focused on that question and demonstrated that ccRCC patients have a relatively lower plasma adiponectin concentration than patients with papillary RCC, chromophobe RCC and unclassified RCC, and that for every 1 µg/ml decrease in serum adiponectin level, there is a 12% increase in the probability of having ccRCC.

Different subtypes of RCC have a diverse pathology, genetics and biology. For example, ccRCC is known for its epigenetic silencing of the *VHL* gene and an HIF pathway alteration. Abnormal *MET* or the *FH* gene may be seen in papillary RCC and chromophobe RCC may be associated with changes in the *BHD* or *FLCN* genes [@B22]. This may explain why some researchers have found different lipid profiles between ccRCC and non-ccRCC [@B23], [@B24]. It is also possible that the tumors themselves have the ability to secrete cytokines. Schips et al. showed that insulin-like growth factor was expressed differentially among different tumor types, and it was detected in 110 (82.1%) of 134 clear cell, eight (36%) of 22 chromophobe, and three (15%) of 20 papillary RCCs (P \< 0.001) [@B25]. In another study, the authors found that transforming growth factor (TGF)-alpha and fibroblast growth factor (FGF) also have different secretion rates in different RCC subtypes [@B26]. It is also possible that sometimes the expression of adiponectin in adipose tissues is tumor guided, considering that inflammatory conditions may affect gene expression and the function of human adipose tissue-derived mesenchymal stem cells [@B27]. Conversely, results from a genome-wide association study (GWAS) identified an rs718314 in inositol 1, 4, 5-triphosphate receptor, type 2 (ITPR2) gene which is both associated with RCC cancer risk and Waist-to-Hip Ratio, reminding us that obesity and RCC may have a parallel cause [@B28]. Additionally, our research group previously reported that a single nucleotide polymorphism (rs182052) in the adiponectin gene is significantly associated with ccRCC risk [@B28], indicating that patients with ccRCC may have distinctive adipose metabolic characteristics due to special genetic backgrounds.

It is interesting that VFA achieved statistical significance in univariate analysis for predicting ccRCC, but the effect diminished in multivariate analysis. Taking the following two results into consideration, we believe that the effect of VFA in differentiating ccRCC from other subtypes might be partly attributed to adiponectin levels. One finding was that plasma adiponectin levels outweighed other factors in the multivariate analysis for predicting ccRCC. The other finding was that we confirmed a clear inverse linear correlation between circulating adiponectin levels and VFA. In the past, some studies have shown different effects of serum leptin levels in RCC [@B9], [@B10], [@B29]. In our study, we tested serum leptin levels but did not find any clear correlation either in our entire cohort or in the ccRCC patients only.

The limitations of our study include its retrospective nature without control groups and a relatively small size of 198 patients. There is a certain selection bias because we only recruited patients from our hospital, a single cancer center. In addition, we excluded metastatic cancer patients because cachexia has a significant influence on VFA values. We also excluded patients with extreme plasma adiponectin/leptin concentrations and patients with benign tumors. In addition, we only tested plasma adiponectin and leptin concentrations. As other authors have pointed out, there are many other adipokines released or affected by adipose tissues, such as interleukin-6 (IL-6) [@B30], plasminogen-activator inhibitor type I (PAI-I) [@B31], and adipsin [@B32]. However, adiponectin and leptin receptors on cancer cells are also important factors related to adipokine serum concentrations [@B33], [@B34]. We have initiated an analysis of other cytokines and receptors in RCC patients. Furthermore, basic medical research will be necessary to clarify the mechanism of adiponectin in ccRCC carcinogenesis. Finally, all of the patients recruited in our study are Chinese, so the results of our study may need to be verified in other ethnic populations.

Conclusion
==========

This is the first study to identify an association between serum adiponectin level and different histological types of RCC. Lower plasma adiponectin concentrations are related to an increased incidence of ccRCC and may act as an independent predictor for ccRCC. Our study may help define the chain from obesity to adipose tissue, to cytokines and finally to ccRCC.
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###### 

Patient demographic and clinical characteristics.

  Characteristics           RCC patients                Normal controls             *P* value
  ------------------------- --------------------------- --------------------------- ----------------
  **Gender, N (%)**                                                                 0.888^a^
  Male                      140 (70.7)                  60 (69.8)                   
  Female                    58 (29.3)                   26 (30.2)                   
  **Median (range)**                                                                
  Age, years                54.00 (22-76)               56.00 (23-74)               0.197^b^
  BMI, kg/m^2^              24.22 (16.89-35.91)         24.06 (17.14-29.76)         0.840^b^
  VFA, cm^2^                104.82 (12.39-203.20)       \-                          
  SFA, cm^2^                123.27 (26.36-320.28)       \-                          
  TFA,cm^2^                 243.33 (50.30-468.77)       \-                          
  VFA%, %                   43.30 (18.20-66.73)         \-                          
  Adiponectin, ug/ml        6.33 (1.01-20.70)           9.54 (4.81-25.32)           **\<0.001^c^**
  Leptin, pg/ml             4009.87 (144.39-10468.08)   5416.79 (498.35-13194.02)   **\<0.001^b^**
  **N (%)**                                                                         
  Hypertension              64 (32.3)                   24 (27.9)                   0.488^a^
  Diabetes                  22 (11.1)                   6 (7.0)                     0.387^a^
  Smoking status            78 (39.4)                   27 (31.4)                   0.229^a^
  **Malignant pathology**                                                           
  Clear cell                156 (78.8)                  \-                          
  Papillary                 4 (2.0)                     \-                          
  Chromophobe               28 (14.1)                   \-                          
  Unclassified              10(5.1)                     \-                          

a: *p*-value derived from Fisher\'s exact test; b: *p*-value derived from Student\'s t test; c: *p*-value derived from Mann-Whitney U test.

###### 

Differences of serum adiponectin, leptin level and VFA between ccRCC patients and non-ccRCC patients.

  Pathology   Serum adiponectin level, ug/ml   Serum leptin level, pg/ml   VFA, cm^2^                                                                               
  ----------- -------------------------------- --------------------------- ------------ ----------- --------- --------- --------- ------- -------- -------- ------- -----------
  ccRCC       6.84                             6.01                        3.94         **0.004**   4357.72   4039.31   2319.33   0.940   103.73   107.79   44.63   **0.042**
  Non-ccRCC   9.05                             8.11                        4.97                     4387.93   3883.26   2312.54           87.64    78.85    47.27   

###### 

Univariate analysis and multivariate analysis of predictors for different subtypes of RCC.

  Characteristics       Univariate analysis   Multivariate analysis                                     
  --------------------- --------------------- ----------------------- ----------- ------- ------------- -----------
  Gender (ref.male)     0.460                 0.226-0.934             **0.032**   0.627   0.279-1.409   0.259
  Age (years)           0.981                 0.952-1.011             0.209       0.979   0.948-1.011   0.190
  BMI (kg/m^2^)         0.904                 0.806-1.014             0.086       0.916   0.813-1.031   0.146
  Smoking statue        1.833                 0.874-3.846             0.109       1.228   0.489-3.079   0.662
  Hypertension          0.943                 0.457-1.947             0.875       0.607   0.255-1.444   0.259
  Diabetes              2.941                 0.659-13.125            0.157       1.552   0.316-7.628   0.588
  VFA, cm^2^            0.992                 0.984-1.000             **0.044**   1.003   0.990-1.017   0.637
  Adiponectin (ug/ml)   1.120                 1.037-1.209             **0.004**   1.120   1.037-1.209   **0.004**
  Leptin (ug/ml)        1.000                 1.000-1.000             0.940       1.000   1.000-1.000   0.625

###### 

Association between clinical parameters and plasma adiponectin/leptin levels in the ccRCC subgroup.

  Characteristics                           Serum adiponectin level, ug/ml   Serum leptin level, ug/ml                                                    
  ---------------------------- ------------ -------------------------------- --------------------------- ------ ----------- --------- --------- --------- -------------
  **Gender, N (%)**                                                                                             **0.002**                                 **\<0.001**
  Male                         116 (74.4)   6.15                             5.80                        3.33               3867.89   3668.66   2101.24   
  Female                       40 (25.6)    8.81                             7.56                        4.87               5778.23   5951.87   2361.55   
  **Fuhrman grading, N (%)**                                                                                    0.769                                     0.321
  Ⅰ&Ⅱ                          89 (57.1)    7.05                             5.73                        4.50               4518.12   4162.68   2187.07   
  Ⅲ&Ⅳ                          67 (42.9)    6.56                             6.03                        3.06               4144.66   3842.73   2484.91   
  **Obesity, N (%)**                                                                                            0.787                                     **\<0.001**
  Yes                          38 (24.4)    6.97                             5.57                        4.55               6357.22   6389.28   1824.57   
  No                           118 (75.6)   6.79                             6.03                        3.75               3713.82   3491.73   2087.35   
  **Tumor size, N (%)**                                                                                         0.069                                     0.461
  ≤4cm                         104 (66.7)   6.57                             5.11                        4.08               4454.82   4241.57   2361.11   
  \>4cm                        52 (33.3)    7.38                             7.09                        3.62               4163.53   3542.64   2243.26   
  **Diabetes, N (%)**                                                                                           **0.001**                                 0.239
  Yes                          20 (12.8)    4.31                             4.22                        1.75               4929.27   5087.72   2762.78   
  No                           136 (87.2)   7.21                             6.41                        4.04               4273.67   3971.23   2246.44   
  **Hypertension, N (%)**                                                                                       0.362                                     0.263
  Yes                          50 (32.1)    6.42                             5.55                        4.01               4661.06   5034.98   2339.05   
  No                           106 (67.9)   7.03                             6.33                        3.91               4214.64   3797.49   2307.21   
  **VFA, N (%)**                                                                                                **0.040**                                 **\<0.001**
  \<90 cm^2^                   55 (35.3)    7.75                             7.42                        4.24               2998.96   2217.54   2141.43   
  ≥90 cm^2^                    101 (64.7)   6.34                             5.44                        3.70               5097.64   4583.48   2072.02   

a\. Mann-Whitney U test. b. Student\'s t test.
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